Janus Kinase Inhibitors in the Treatment of Atopic Dermatitis: Military Considerations

Janus kinase (JAK) inhibitors represent one of the newest and most promising additions to the available treatments of atopic dermatitis (AD). Janus kinase inhibitors offer several key benefits over injectable biologics to include more predictable pharmacokinetics, nonimmunogenicity, and flexible dosing, in addition to their oral and topical bioavailability. Recommended laboratory assessments before and during treatment in addition to medication side effects may limit the scope of use in the active-duty military population and specifically within special-duty populations. In this article, we review approved and emerging JAK inhibitors for the treatment of AD as well as important considerations for both military and nonmilitary patient populations.